2 citations
,
August 2021 in “Journal of Clinical Psychopharmacology” An 8-year-old girl's eyebrow hair loss was linked to atomoxetine for ADHD but grew back after stopping the medication.
February 2024 in “International Journal of Pharmaceutics” A new hair loss treatment combining minoxidil and cedrol improves hair growth and reduces side effects.
60 citations
,
June 2007 in “Pharmacology Biochemistry and Behavior” Blocking progesterone metabolism can cause depression-like behavior in mice.
January 2014 in “Anales Médicos de la Asociación Médica del Centro Médico ABC” The treatment effectively promoted hair growth with minimal side effects.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
Finasteride is more stable in sunlight than Diclofenac and Naproxen.
July 2019 in “Journal of Drug Delivery and Therapeutics” The method accurately measures finasteride in bulk and dosage forms.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
1 citations
,
January 2013 in “Hair therapy & transplantation” The document does not provide information about hair loss treatment.
1 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
January 2023 in “Anais do Congresso Brasileiro Interdisciplinar em Ciência e Tecnologia.” Optimizing the method improved minoxidil measurement accuracy and efficiency.
May 2018 in “Más dermatología” The higher dose supplement was more effective in treating female hair loss.
15 citations
,
November 2017 in “Drug Delivery and Translational Research” Certain extracts from Curcuma aeruginosa Roxb. and germacrone can boost the skin's absorption of minoxidil, a hair growth promoter, making it more effective.
1 citations
,
January 2013 in “PubMed” Adenosine led to higher patient satisfaction than minoxidil for hair loss treatment.
May 2022 in “Endocrine Abstracts” Finasteride may cause sexual dysfunction by reducing epinephrine levels.
March 2005 in “Journal of The American Academy of Dermatology” The two lotions used day and night may be a good alternative to minoxidil for hair loss treatment with better cosmetic effects and tolerance.
April 2022 in “Reactions Weekly” April 2025 in “International Journal of Pharmaceutics” Liposomes improve minoxidil delivery to hair follicles, enhancing treatment for hair loss.
January 2018 in “Journal of analytical, bioanalytical and separation techniques” 3 citations
,
March 2012 in “Arab Journal of Urology” Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.
66 citations
,
September 1982 in “Biochemical Pharmacology” Liver enzyme helps minoxidil work better for blood vessel relaxation.
February 2026 in “Journal of Dermatology and Skin Science” Finasteride can cause serious mental health issues, so it's advised to avoid it for hair loss.
64 citations
,
June 2009 in “Journal of The American Academy of Dermatology” Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
4 citations
,
January 2011 in “Analytical Letters” The method quickly and accurately measures minoxidil in drugs, comparable to standard techniques.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
May 2025 in “Actas Dermo-Sifiliográficas” High-dose oral minoxidil can improve hair growth but may cause side effects.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
40 citations
,
December 2019 in “Neurobiology of Stress” Neuroactive steroids show promise for treating mental and neurological disorders by targeting GABA_A receptors.
November 2020 in “International journal of pharmaceutical compounding” A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.